Evidence map›Paper›PMID 39575283›Full record

ArticleWorld journal of gastrointestinal surgery2024

Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy.

Liang Wang, Yong-Zhi Diao, Xin-Fu Ma, Yu-Shuang Luo, Qi-Jing Guo, Xiao-Qian Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liang WangDepartment of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
Yong-Zhi DiaoDepartment of Gastroenterology, The First People's Hospital of Xining, Xining 810000, Qinghai Province, China.
Xin-Fu MaDepartment of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
Yu-Shuang LuoDepartment of Medical Oncology, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
Qi-Jing GuoDepartment of Medical Oncology, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
Xiao-Qian ChenDepartment of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China. cxq925@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt present, immune checkpoint inhibitors (ICIs) remain the 1

aimTo investigate the effects of ICIs combined with bevacizumab monoclonal antibody on tumor immune cells in MSS/pMMR advanced CRC patients with first-line treatment failure.

methodsA total of 110 MSS/pMMR patients with advanced CRC after first-line treatment failure in the Affiliated Hospital of Qinghai University were enrolled for a randomized controlled trial. In short, patients in the experimental group (

resultsThe positive expression rates of CD8 (+) T lymphocytes (30%

conclusionICIs in combination with bevacizumab can not only improve the patient's prognosis but also yield safe and controllable adverse drug reactions in patients suffering from MSS/pMMR advanced CRC after failure to a 1

Indexed as

BevacizumabCancer-associated fibroblastsColorectal cancerCytotoxic T lymphocytesImmune checkpoint inhibitorsTumor-associated macrophages

Identifiers

PMID39575283
PMCPMC11577402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.